Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MASP2 | O00187 | 1/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | HPD | P32754 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 6/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26218846 | 0.87 | ALDH1A1 (0.51) | CYP2C19ALDH1A1HPGDKDM4EUSP2 | |
| SCHEMBL27641472 | 0.83 | MAPT (0.53) | CYP2C19ALDH1A1HPGDMASP2F2 | |
| SCHEMBL34420057 | 0.81 | ALDH1A1 (0.57) | CYP2C19ALDH1A1HPGDMASP2F2 | |
| SCHEMBL1632412 | 0.81 | ALDH1A1 (0.57) | CYP2C19ALDH1A1HPGDMASP2F2 | |
| SCHEMBL10980033 | 0.81 | MAPT (0.61) | ALDH1A1HPGDKDM4EMASP2F2 | |
| Diphenylmethanol SCHEMBL8067155 | 0.81 | MAPT (0.56) | CYP2C19ALDH1A1HPGDKDM4EUSP2 | |
| SCHEMBL12714642 | 0.80 | MASP2 (0.46) | CYP2C19ALDH1A1HPGDKDM4EMASP2 | |
| SCHEMBL4076795 | 0.80 | L3MBTL1 (0.51) | ALDH1A1MAPTTDP1SMN1; SMN2KMT2A | |
| SCHEMBL3459815 | 0.79 | PTGDR2 (0.50) | CYP2C19ALDH1A1HPGDMASP2F2 | |
| SCHEMBL14453659 | 0.79 | MASP2 (0.54) | ALDH1A1HPGDKDM4EMASP2F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7294647-B2 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 2007-11-13 | — | — | US | disclosed |
| CN-1972925-A | Substituted bisarylurea derivatives | MERCK PATENT GMBH (DE) | 2007-05-30 | — | — | CN | disclosed |
| EP-1730111-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GmbH (DE) | 2006-12-13 | — | — | EP | disclosed |
| US-6960612-B2 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 2005-11-01 | — | — | US | disclosed |
| WO-2005075425-A2 | SUBSTITUTED BISARYLUREA DERIVATIVES AS KINASE INHIBITORS | MERCK PATENT GMBH (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION | 2005-01-27 | — | — | US | disclosed |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION | 2004-11-04 | — | — | US | disclosed |
| EP-1112252-A4 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORP (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6750216-B2 | HETEROCYCLIC AMINES SUCH AS 2-(2-(N-METHYLSULFAMOYL)-4-METHOXY -PHENYL)-N-METHYL-N-((1S)-1-PHENYL-2-((1-PYRROLIDINYL)ETHYL)) ACETAMIDE, ADMINISTERED AS ANALGESICS | ADOLOR CORPORATION | 2004-06-15 | — | — | US | disclosed |
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | KRUSE LAWRENCE I (US) | 2003-12-25 | — | — | US | disclosed |
| US-5981513-A | ADMINISTERING ANTI-PRUITIC COMPOUNDS TO PATIENTS | ADOLOR CORPORATION (US) | 1999-11-09 | — | — | US | disclosed |
| US-5945443-A | Kappa agonist compounds and pharmaceutical formulations thereof | ADOLOR CORPORATION (US) | 1999-08-31 | — | — | US | disclosed |
| WO-1999003468-A1 | KAPPA AGONIST COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND METHOD OF PREVENTION AND TREATMENT OF PRURITUS THEREWITH | ADOLOR CORPORATION (US) | 1999-01-28 | — | — | WO | disclosed |
| EP-0885199-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | Adolor Corporation (US) | 1998-12-23 | — | — | EP | disclosed |
| US-5763445-A | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith | ADOLOR CORPORATION (US) | 1998-06-09 | — | — | US | disclosed |
| US-5744458-A | ANALGESICS | ADOLOR CORPORATION (US) | 1998-04-28 | — | — | US | disclosed |
| US-5711966-A | REPLACEMENT OF HALOFANTRINE AVOIDS CARDIAC ARRHYTHMIAS | ARMY MEDICAL RESEARCH & MATERIEL COMMAND, GOVERNMENT OF THE UNITED STATES, U.S. | 1998-01-27 | — | — | US | disclosed |
| US-5688955-A | ANALGESICS | ADOLOR CORPORATION (US) | 1997-11-18 | — | — | US | disclosed |
| WO-1997032857-A1 | KAPPA AGONIST COMPOUNDS AND PHARMACEUTICAL FORMULATIONS THEREOF | ADOLOR CORPORATION (US) | 1997-09-12 | — | — | WO | disclosed |
| WO-1997007792-A1 | DESBUTYLHALOFANTRINE COMPOSITIONS AND USE | DEPARTMENT OF THE ARMY, US GOVERNMENT (US) | 1997-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236248-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | CYP2C19 1025/4885ALDH1A1 3668/4885HPGD 2149/4885 |
| US-20040220112-A1 | Kappa agonist compounds, pharmaceutical formulations and method of prevention and treatment of pruritus therewith | OPRK1, OPRD1, OPRM1 | CYP2C19 1085/4885ALDH1A1 3340/4885HPGD 1894/4885 |
| US-20050020576-A1 | Kappa agonist compounds and pharmaceutical formulations thereof | OPRK1, OPRD1, OPRM1 | CYP2C19 618/4885ALDH1A1 3020/4885HPGD 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.